Bio-Fd&C바이오에프디엔씨
251120 · KOSDAQ · ₩251120 · 바이오에프디엔씨
- Market cap
- ₩80B
- Enterprise value
- ₩26B
- P/E
- 12.5×
- P/B
- 1.1×
- Dividend yield
- 0.0%
- ROE
- 8.8%
- Net margin
- 32.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−46.8% from the high
₩6,330Today: ₩8,830 – ₩9,440₩17,300
Returns
- 1W−7.3%
- 1M−3.4%
- 3M+28.3%
- 6M−35.7%
- YTD−41.8%
- 1Y−45.1%
- Volume today
- 12,552
- 0.6× the 20-day average
- Traded today
- ₩112M
- Listed shares
- 8,695,700
- EPS (12 months)
- ₩737
- Earnings yield 8.0%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 37 of 100 (50 is a normal day for this stock).
- MomentumFlat-3.3% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Bio-Fd&C stock overview
Bio-Fd&C (바이오에프디엔씨, KRX: 251120) is listed on KOSDAQ, in the Biotech & Pharma sector. Bio FDNC develops and manufactures plant-cell-derived active ingredients, such as plant cell lines, growth factors and peptides, used as raw materials in cosmeceuticals, health functional foods and pharmaceuticals. Its shares closed at ₩9,200 on Oct 29, 2026, down 0.86% on the day, giving it a market value of ₩80B.
Key facts
- Market cap
- ₩80B
- Sector
- Biotech & Pharma
- Latest price change
- −0.86%
- As of
- Oct 29, 2026
- Main business
- Bio FDNC develops and manufactures plant-cell-derived active ingredients, such as plant cell lines, growth factors and peptides, used as raw materials in cosmeceuticals, health functional foods and pharmaceuticals.
Quick answers about Bio-Fd&C
- What does Bio-Fd&C do?
- Bio FDNC develops and manufactures plant-cell-derived active ingredients, such as plant cell lines, growth factors and peptides, used as raw materials in cosmeceuticals, health functional foods and pharmaceuticals. The company supplies these ingredients to customers in Korea and abroad, including fragrance and flavor companies, and its products are mainly sold as cosmetic raw materials, with plans to commercialize plant-cell-based pharmaceuticals over the medium to long term. Its facilities are located in Incheon Songdo and Hwasun, Jeollanam-do, South Korea.
- What is the market cap of Bio-Fd&C?
- The market capitalisation of Bio-Fd&C was ₩80B at the close on Oct 29, 2026.
- Who are the largest shareholders of Bio-Fd&C?
- According to the latest official filings, the largest reported holders are Mo Sang-hyeon (31.48%, as of Oct 6, 2026); Jeong Dae-hyun (10.32%, as of Apr 22, 2025); Kim Su-jeong (1.78%, as of Apr 24, 2025).
- When is the next earnings report from Bio-Fd&C?
- Korean companies rarely announce results dates in advance. Based on when Bio-Fd&C filed the same report in past years, its next 3q results is expected between Nov 12, 2026 and Nov 14, 2026.
- Does the National Pension Service own Bio-Fd&C?
- Yes. The National Pension Service held 0.59% of Bio-Fd&C shares as of Dec 31, 2025.
Company profile
Bio FDNC develops and manufactures plant-cell-derived active ingredients, such as plant cell lines, growth factors and peptides, used as raw materials in cosmeceuticals, health functional foods and pharmaceuticals. The company supplies these ingredients to customers in Korea and abroad, including fragrance and flavor companies, and its products are mainly sold as cosmetic raw materials, with plans to commercialize plant-cell-based pharmaceuticals over the medium to long term. Its facilities are located in Incheon Songdo and Hwasun, Jeollanam-do, South Korea.
Written by AI from the company's latest annual report.
- Korean name
- 바이오에프디엔씨
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 모상현, 정대현
- Founded
- Nov 2005
- Listed
- Feb 2022
- Listed shares
- 8,695,700
- Fiscal year ends
- Month 12
- Website
- www.biofdnc.com
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent filings
See all- Amended: 5%+ holding reportOct 6, 2026
- 5%+ holding reportOct 6, 2026
- Investor relations (IR) eventSep 7, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- 5%+ holding reportJul 24, 2026
Titles in Korean until English translations are added.
Also known as: Bio-Fd&C / 바이오에프디엔씨 / 251120 / KRX:251120
Source: KRX statistical information